In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $3.66.
Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Onconova Therapeutics, and Actinium Pharmaceuticals. According to TipRanks, Pantginis has an average return of 0.5% and a 37.72% success rate on recommended stocks.
Currently, the analyst consensus on Aprea Therapeutics is a Moderate Buy with an average price target of $18.00.
See today’s best-performing stocks on TipRanks >>
APRE market cap is currently $13.66M and has a P/E ratio of -0.64.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded in 2002 and is headquartered in Boston, MA.
Read More on APRE:
- Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
- APRE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
- Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
- Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
